Key Highlights
- ImpriMed has closed a $23 million Series A funding round led by SBVA, with participation from multiple investors including HRZ Han River Partners and SK Telecom.
- The funding will enable expansion into human oncology, increasing headcount, and broadening business and research development.
- ImpriMed’s technology, initially focused on veterinary medicine, has been successfully deployed in over 250 veterinary hospitals, completing over 15,000 blood cancer tests for pets.
Source: Business Wire
Notable Quotes
- “As the importance of precision medicine in conquering cancer continues to grow, ImpriMed has been producing significant results in the treatment of canine cancer, based on an abundance of clinical data,” – Jay Choi, Principal at SBVA
- “This significant funding, secured in a challenging global investment landscape, is a strong endorsement of our technological innovation and growth trajectory.” – Sungwon Lim, CEO at ImpriMed
SoH's Take
ImpriMed’s latest funding is a significant milestone in the field of precision medicine. The shift from veterinary to human oncology is not just a business expansion, but a transformative step in cancer treatment. ImpriMed’s AI-driven technology offers a new dimension in understanding and predicting drug responses, potentially revolutionizing oncology. The implications for patient outcomes and healthcare efficiency are immense, positioning ImpriMed as a trailblazer in the rapidly evolving landscape of medical technology. This advancement also highlights the increasingly vital role of AI in healthcare, marking a promising future for personalized medicine.
